Clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS) are considered precursor diseases to hematologic malignancies, indicating early stages of blood disorders that may progress to more serious conditions such as leukemia or myelodysplastic syndromes (MDS).
In this podcast, Uma Borate, MD, The Ohio State University, Columbus, OH, Kelly Bolton, MD, PhD, Washington University School of Medicine, St. Louis, MO, and Eric Padron, MD, Moffitt Cancer Center, Tampa, FL, discuss knowledge gaps in the field, share insights from ongoing trials, and further emphasize the importance of multidisciplinary teamwork in managing CHIP and CCUS. This episode is part of our podcast series from the 2024 Intercepting Blood Cancers (IBC) Workshop, which was held in Lisbon, Portugal.
The post CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for approaching patients with myeloid precursors appeared first on VJHemOnc.